Mayne loses UK appeal on generic cancer drug
Monday, 21 February, 2005
Mayne Group will book a AUD$5 million one-off charge in its first-half results after a UK appeal court ruled its version of the cancer drug epirubicin infringed a patent on the original drug.
Mayne had been looking to win approval to sell its formulation of epirubicin, used in breast cancer chemotherapy, before the patent held by Pharmacia Italia, a unit of Pfizer, expired in June 2006.
The English High Court had ruled in favour of Mayne last October, but the Court of Appeal overturned the ruling on a point of law.
Mayne said the AUD$5 million charge it will record reflects the top end of estimated legal and other costs associated with the UK litigation. Analysts expect Mayne to report a net profit of around AUD$35 million before one-offs for the first-half when it releases its results on February 23.
MV Hondius passengers return to Australia under strict infection control measures
The Australian CDC has provided an update on hantavirus risk to Australians and infection...
$96m RNA Research and Manufacturing Facility opens in NSW
The new 4500 sqm RNA Research and Manufacturing Facility within the Macquarie University...
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
